autologous chimeric switch receptor modified t cells
Cell therapyexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2016 (NCT02937844)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetImmunity, passive
Immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous chimeric switch receptor modified t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05098171 | Early Phase 1 (Phase 1) | Sep 26, 2021 | Huazhong University of Science and Technology, Shanghai Gencells Therapeutics Co., Ltd. |
| NCT02937844 | Phase 1 | Jul 1, 2016 | Capital Medical University, Marino Biotechnology Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Marino Biotechnology Co., Ltd. | For profit | 1 | 0 | 1 | 2016 |
| Shanghai Gencells Therapeutics Co., Ltd. | For profit | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1